ACADIA Pharmaceuticals Inc.
ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 developmā¦ read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$25.33
Price+3.26%
$0.80
1Y
Price
Market Cap
$4.273b
Mid
Price/Earnings 3y Avg5y Avg
19.1x
Premium
Premium
Financials Overview
Key metrics over the past few years+10.1%
EBITDA Margin+8.0%
Net Profit Margin+14.1%
Free Cash Flow MarginRevenue
$1.019b
+12.0%
1y CAGR+19.8%
3y CAGR+17.2%
5y CAGREarnings
$222.160m
+97.2%
1y CAGR+46.7%
3y CAGR+45.1%
5y CAGREPS
$1.33
+97.3%
1y CAGR+47.4%
3y CAGR+45.9%
5y CAGRBook Value
$822.382m
$1.226b
Assets$403.173m
Liabilities$44.601m
DebtDebt to Assets
3.6%
23.1x
Debt to EBITDAFree Cash Flow
$187.086m
+201.4%
1y CAGR+97.0%
3y CAGR+75.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company